Clinical Trial Update: Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults [Phase 1]

View source ↗

Summary

Phase I trial comparing safety and immunogenicity of MVA85A-IMX313 to MVA85A in BCG-vaccinated adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)
• MVA85A-IMX313

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis (TB) | Phase 1 | Status: COMPLETED